At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 331 enrolled
Drug / intervention
ZD6474 (Vandetanib)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
In Brief
A Phase 3 clinical trial evaluating ZD6474 (Vandetanib) for Thyroid Cancer. Completed, enrolled 331 participants across 127 sites in 24 countries.
Detailed Summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesAustralia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, South Korea, Spain, Sweden, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedDec 2006
Primary CompletionJul 2009
Study CompletionJul 2024
TodayJul 2026
First PostedDec 13, 2006
Enrollment StartNov 23, 2006
Primary CompletionJul 31, 2009
Study CompletionJul 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 19.6 years ago
Interventions
ZD6474 (Vandetanib)drug
once daily oral tablet